What's Going On With Nano-Cap NKGen Biotech Stock On Monday?
What's Going On With Nano-Cap NKGen Biotech Stock On Monday?
NKGen Biotech Inc (NASDAQ:NKGN) shares traded higher on Monday, with a strong session volume of 19.25 million, compared to an average 100-day volume of 2.85 million, according to data from Benzinga Pro.
根据Benzinga Pro的数据，NKGen Biotech Inc（纳斯达克股票代码：NKGN）周一股价上涨，强劲的交易量为1,925万个，而100天的平均交易量为285万个。
However, there is no news to justify the +20% increase in the stock price.
但是，没有消息可以证明股价上涨了20％是合理的。
NKGen Biotech will present details about its NK cell therapy for neurodegenerative disease, review its preclinical data for Parkinson's disease, and highlight clinical safety and efficacy data from the recently completed Phase 1 trial of SNK01 for Alzheimer's disease at the 12th Annual Alzheimer's & Parkinson's Drug Development Summit.
NKGen Biotech将在第12届阿尔茨海默氏症和帕金森氏症药物开发年度峰会上介绍其神经退行性疾病的NK细胞疗法的详细信息，审查其帕金森氏病的临床前数据，并重点介绍最近完成的针对阿尔茨海默氏病的 SNK01 1 期试验的临床安全性和有效性数据。
Earlier this month, NKGen Biotech closed $5 million in second-lien convertible loan funding with a term of 30 months, augmenting approximately $4.75 in gross cash proceeds from prior 2024 funding to date.
本月早些时候，NKGen Biotech完成了500万美元的第二留置权可转换贷款融资，期限为30个月，增加了2024年迄今为止融资的约4.75美元的总现金收益。
"We are intently focused on our upcoming Phase 2 Alzheimer's clinical trial and recently submitted an IND for Parkinson's disease while streamlining our resources for maximum efficiency. Accordingly, we have successfully reduced our monthly burn rate for operations and clinical trials by almost 50%. In addition, we have several catalysts expected this year, including data readouts (both safety and cognitive) for the Phase 1 portion of our moderate Alzheimer's trial and the initiation of Phase 2," said Paul Song, Chairman and CEO.
“我们全神贯注于即将到来的2期阿尔茨海默氏症临床试验，最近提交了帕金森氏病的临床试验，同时精简了资源以实现最大效率。因此，我们成功地将手术和临床试验的每月消耗率降低了近50％。此外，我们预计今年将有几种催化剂，包括我们中度阿尔茨海默氏症试验第一阶段的数据读取（安全和认知两方面）以及第二阶段的启动，” 董事长兼首席执行官保罗·宋说。
Price Action: NKGN shares are up 29.30% at $1.43 at the last check Monday.
价格走势：周一最后一次支票时，NKGN股价上涨29.30％，至1.43美元。
Photo by hans-reniers for Unsplash
由 hans-reniers 为 Unsplash 拍摄的照片
译文内容由第三方软件翻译。